Vapreotide | CAS#103222-11-3 | antineoplasm

MedKoo Cat#: 598013 | Name: Vapreotide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vapreotide is used in therapy of experimental pancreatic neoplasms in hamsters.

Chemical Structure

Vapreotide

CAS#103222-11-3 (free)

Theoretical Analysis

MedKoo Cat#: 598013

Name: Vapreotide

CAS#: 103222-11-3 (free)

Chemical Formula: C57H70N12O9S2

Exact Mass: 1130.4830

Molecular Weight: 1131.38

Elemental Analysis: C, 60.51; H, 6.24; N, 14.86; O, 12.73; S, 5.67

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 450.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

936560-75-7 (diacetate) 849479-74-9 (acetate) 103222-11-3 (free)

Synonym

Vapreotide; Sanvar IR; Vapreotidum; RC 160; RC-160; RC160;

IUPAC/Chemical Name

(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-N-((S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-(4-hydroxybenzyl)-7-isopropyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

InChi Key

SWXOGPJRIDTIRL-DOUNNPEJSA-N

InChi Code

1S/C57H70N12O9S2/c1-32(2)49-57(78)68-48(55(76)64-44(50(60)71)26-35-28-61-41-16-8-6-14-38(35)41)31-80-79-30-47(67-51(72)40(59)24-33-12-4-3-5-13-33)56(77)65-45(25-34-19-21-37(70)22-20-34)53(74)66-46(27-36-29-62-42-17-9-7-15-39(36)42)54(75)63-43(52(73)69-49)18-10-11-23-58/h3-9,12-17,19-22,28-29,32,40,43-49,61-62,70H,10-11,18,23-27,30-31,58-59H2,1-2H3,(H2,60,71)(H,63,75)(H,64,76)(H,65,77)(H,66,74)(H,67,72)(H,68,78)(H,69,73)/t40-,43+,44+,45+,46-,47+,48+,49+/m1/s1

SMILES Code

CC([C@@H]1NC([C@@H](NC([C@H](NC([C@@H](NC([C@@H](NC([C@@H](Cc2ccccc2)N)=O)CSSC[C@@H](C(N[C@H](C(N)=O)Cc(c[nH]3)c4c3cccc4)=O)NC1=O)=O)Cc5ccc(O)cc5)=O)Cc(c[nH]6)c7c6cccc7)=O)CCCCN)=O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,131.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Saha S, Sharma A, Bhowmik D, Kumar D. Investigation into in silico and in vitro approaches for inhibitors targeting MCM10 in Leishmania donovani: a comprehensive study. Mol Divers. 2024 May 9. doi: 10.1007/s11030-024-10876-y. Epub ahead of print. PMID: 38722455. 2: Ali W, Jamal S, Gangwar R, Ahmed F, Sharma R, Agarwal M, Sheikh JA, Grover A, Grover S. Targeting of essential mycobacterial replication enzyme DnaG primase revealed Mitoxantrone and Vapreotide as novel mycobacterial growth inhibitors. Mol Inform. 2024 Mar;43(3):e202300284. doi: 10.1002/minf.202300284. Epub 2024 Feb 6. PMID: 38123523. 3: Tilak M, Tewari M, Shukla HS. Octreotide and postoperative pancreatic fistula after pancreaticoduodenectomy: What we know so far? A narrative review. Indian J Cancer. 2023 Apr-Jun;60(2):152-159. doi: 10.4103/ijc.IJC_280_21. PMID: 37530235. 4: Uzunhisarcıklı E, Yerer MB. Neuroprotective Effects of Vapreotide on Tau Transfection-Induced Neurodegeneration. Neurotox Res. 2022 Dec;40(6):1824-1837. doi: 10.1007/s12640-022-00588-2. Epub 2022 Nov 15. PMID: 36378411. 5: Schorn S, Vogel T, Demir IE, Demir E, Safak O, Friess H, Ceyhan GO. Do somatostatin-analogues have the same impact on postoperative morbidity and pancreatic fistula in patients after pancreaticoduodenectomy and distal pancreatectomy? - A systematic review with meta-analysis of randomized- controlled trials. Pancreatology. 2020 Dec;20(8):1770-1778. doi: 10.1016/j.pan.2020.10.043. Epub 2020 Oct 22. PMID: 33121847. 6: Borgio JF, Alsuwat HS, Al Otaibi WM, Ibrahim AM, Almandil NB, Al Asoom LI, Salahuddin M, Kamaraj B, AbdulAzeez S. State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2. Arch Med Sci. 2020 Apr 17;16(3):508-518. doi: 10.5114/aoms.2020.94567. PMID: 32399096; PMCID: PMC7212215. 7: Abdellatif AAH. A plausible way for excretion of metal nanoparticles via active targeting. Drug Dev Ind Pharm. 2020 May;46(5):744-750. doi: 10.1080/03639045.2020.1752710. Epub 2020 Apr 15. PMID: 32250174. 8: Liu H, Li L, Luo L, He Y, Cong C, He Y, Hao Z, Gao D. Green dual-template synthesis of AgPd core-shell nanoparticles with enhanced electrocatalytic activity. Nanotechnology. 2020 Jan 17;31(3):035603. doi: 10.1088/1361-6528/ab4836. Epub 2019 Sep 26. PMID: 31557747. 9: Adiamah A, Arif Z, Berti F, Singh S, Laskar N, Gomez D. The Use of Prophylactic Somatostatin Therapy Following Pancreaticoduodenectomy: A Meta- analysis of Randomised Controlled Trials. World J Surg. 2019 Jul;43(7):1788-1801. doi: 10.1007/s00268-019-04956-6. PMID: 30798417. 10: Abdellatif AAH, Abou-Taleb HA, Abd El Ghany AA, Lutz I, Bouazzaoui A. Targeting of somatostatin receptors expressed in blood cells using quantum dots coated with vapreotide. Saudi Pharm J. 2018 Dec;26(8):1162-1169. doi: 10.1016/j.jsps.2018.07.004. Epub 2018 Jul 20. PMID: 30532637; PMCID: PMC6260484. 11: Zhu R, Li Y, Zhang X, Bian K, Yang M, Cong C, Cheng X, Zhao S, Li X, Gao D. Vapreotide-mediated hierarchical mineralized Ag/Au nanoshells for photothermal anti-tumor therapy. Nanotechnology. 2019 Feb 1;30(5):055602. doi: 10.1088/1361-6528/aaf0db. PMID: 30520422. 12: Yin T, Li Y, Bian K, Zhu R, Liu Z, Niu K, Liu H, Gao Z, Gao D. Self-assembly synthesis of vapreotide‑gold hybrid nanoflower for photothermal antitumor activity. Mater Sci Eng C Mater Biol Appl. 2018 Dec 1;93:716-723. doi: 10.1016/j.msec.2018.08.017. Epub 2018 Aug 7. PMID: 30274105. 13: Prévôt TD, Gastambide F, Viollet C, Henkous N, Martel G, Epelbaum J, Béracochéa D, Guillou JL. Roles of Hippocampal Somatostatin Receptor Subtypes in Stress Response and Emotionality. Neuropsychopharmacology. 2017 Jul;42(8):1647-1656. doi: 10.1038/npp.2016.281. Epub 2016 Dec 16. PMID: 27986975; PMCID: PMC5518893. 14: Fortune BE, Garcia-Tsao G, Ciarleglio M, Deng Y, Fallon MB, Sigal S, Chalasani NP, Lim JK, Reuben A, Vargas HE, Abrams G, Lewis MD, Hassanein T, Trotter JF, Sanyal AJ, Beavers KL, Ganger D, Thuluvath PJ, Grace ND, Groszmann RJ; Vapreotide Study Group. Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage: Analysis of a US Multicenter Prospective Study. J Clin Gastroenterol. 2017 May-Jun;51(5):446-453. doi: 10.1097/MCG.0000000000000733. PMID: 27779613; PMCID: PMC5403609. 15: Li XT, Tang W, Jiang Y, Wang XM, Wang YH, Cheng L, Meng XS. Multifunctional targeting vinorelbine plus tetrandrine liposomes for treating brain glioma along with eliminating glioma stem cells. Oncotarget. 2016 Apr 26;7(17):24604-22. doi: 10.18632/oncotarget.8360. PMID: 27029055; PMCID: PMC5029727. 16: Feng Q, Yu MZ, Wang JC, Hou WJ, Gao LY, Ma XF, Pei XW, Niu YJ, Liu XY, Qiu C, Pang WH, Du LL, Zhang Q. Synergistic inhibition of breast cancer by co- delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles. Biomaterials. 2014 Jun;35(18):5028-38. doi: 10.1016/j.biomaterials.2014.03.012. Epub 2014 Mar 27. PMID: 24680191. 17: Banerjee S, Wiggins WJ, Geoghegan JL, Anthony CT, Woltering EA, Masterson DS. Novel synthesis of various orthogonally protected Cα-methyllysine analogues and biological evaluation of a vapreotide analogue containing (S)-α-methyllysine. Org Biomol Chem. 2013 Oct 7;11(37):6307-19. doi: 10.1039/c3ob41282b. PMID: 23942875. 18: Spitsin S, Tuluc F, Meshki J, Ping Lai J, Tustin Iii R, Douglas SD. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor. Neuroimmunomodulation. 2013;20(5):247-55. doi: 10.1159/000350468. Epub 2013 Jul 5. PMID: 23921645; PMCID: PMC3839635. 19: Zhao P, Canals M, Murphy JE, Klingler D, Eriksson EM, Pelayo JC, Hardt M, Bunnett NW, Poole DP. Agonist-biased trafficking of somatostatin receptor 2A in enteric neurons. J Biol Chem. 2013 Sep 6;288(36):25689-25700. doi: 10.1074/jbc.M113.496414. Epub 2013 Aug 2. PMID: 23913690; PMCID: PMC3764777. 20: Wang Z, Ma W, Wang J, Deng J, Yuan M, Zhao M, Jia L, Yang W, Zhang R, Qin W, Chu D, Li G. Imaging and therapy of hSSTR2-transfected tumors using radiolabeled somatostatin analogs. Tumour Biol. 2013 Aug;34(4):2451-7. doi: 10.1007/s13277-013-0796-x. Epub 2013 Apr 19. PMID: 23605323.